Nathan Petty

2.1k total citations
29 papers, 1.3k citations indexed

About

Nathan Petty is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Nathan Petty has authored 29 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 21 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Nathan Petty's work include Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (8 papers). Nathan Petty is often cited by papers focused on Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (8 papers). Nathan Petty collaborates with scholars based in United States. Nathan Petty's co-authors include Bart Barlogie, John Crowley, Frits van Rhee, Antje Hoering, John D. Shaughnessy, Sarah Waheed, Elias Anaissie, Joshua Epstein, Yazan Alsayed and Maurizio Zangari and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Nathan Petty

26 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan Petty United States	16	1.2k	955	681	161	86	29	1.3k
Dan Spoon United States	9	1.3k 1.1×	854 0.9×	671 1.0×	171 1.1×	56 0.7×	11	1.4k
D Bracy United States	14	1.5k 1.2×	874 0.9×	692 1.0×	204 1.3×	91 1.1×	17	1.6k
Patrizia Falco Italy	16	1.2k 1.0×	1.0k 1.1×	763 1.1×	153 1.0×	62 0.7×	41	1.4k
Zandra Klippel United States	14	523 0.4×	436 0.5×	505 0.7×	56 0.3×	31 0.4×	34	790
Claudius Rudin United Kingdom	7	500 0.4×	352 0.4×	532 0.8×	73 0.5×	73 0.8×	16	845
Dominik Dytfeld Poland	14	1.0k 0.8×	920 1.0×	652 1.0×	113 0.7×	64 0.7×	75	1.3k
Himal Amin United States	8	1.1k 0.9×	870 0.9×	685 1.0×	197 1.2×	61 0.7×	13	1.4k
Mohammad R. Nowrousian Germany	15	359 0.3×	245 0.3×	237 0.3×	114 0.7×	134 1.6×	31	693
Kelly Godby United States	11	695 0.6×	501 0.5×	435 0.6×	99 0.6×	44 0.5×	52	789
Jessica Anderson United States	3	682 0.6×	765 0.8×	406 0.6×	137 0.9×	103 1.2×	5	1.0k

Countries citing papers authored by Nathan Petty

Since Specialization

Citations

This map shows the geographic impact of Nathan Petty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Petty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Petty more than expected).

Fields of papers citing papers by Nathan Petty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Petty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Petty. The network helps show where Nathan Petty may publish in the future.

Co-authorship network of co-authors of Nathan Petty

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Petty. A scholar is included among the top collaborators of Nathan Petty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Petty. Nathan Petty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davies, Faith E., Adam Rosenthal, Leo Rasche, et al.. (2018). Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 103(6). 1047–1053. 40 indexed citations

McDonald, James E., Marcus M. Kessler, Amy Buros, et al.. (2016). Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical Cancer Research. 23(8). 1981–1987. 92 indexed citations

Khan, Rashid, Madhav V. Dhodapkar, Adam Rosenthal, et al.. (2015). Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 100(9). 1214–1221. 34 indexed citations

Singh, Zeba N., Yogesh Jethava, Ginell R. Post, et al.. (2015). Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. Clinical Case Reports. 3(3). 183–192. 1 indexed citations

Papanikolaou, Xanthos, Jackie Szymonifka, Adam Rosenthal, et al.. (2013). Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. Haematologica. 98(7). 1147–1153. 10 indexed citations

Dhodapkar, Madhav V., Rachel Sexton, Sarah Waheed, et al.. (2013). Clinical, genomic, and imaging predictors of malignancy: Analysis of the first U.S. cooperative group prospective clinical trial in asymptomatic monoclonal gammopathies (SWOG S0120).. Journal of Clinical Oncology. 31(15_suppl). 8515–8515.

Rosenthal, Adam, Christoph Heuck, Frits van Rhee, et al.. (2013). Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx). Blood. 122(21). 1870–1870.

Heuck, Christoph, Jackie Szymonifka, John D. Shaughnessy, et al.. (2012). Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1. Clinical Cancer Research. 18(19). 5499–5506. 13 indexed citations

Usmani, Saad Z., Bijay Nair, Pingping Qu, et al.. (2012). Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 26(11). 2398–2405. 45 indexed citations

10.

Usmani, Saad Z., Rachel Sexton, Antje Hoering, et al.. (2012). Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 120(8). 1597–1600. 45 indexed citations

11.

Barlogie, Bart, Elias Anaissie, Frits van Rhee, et al.. (2010). Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms. Journal of Clinical Oncology. 28(18). 3023–3027. 28 indexed citations

12.

Nair, Bijay, Nathan Petty, Sarah Waheed, et al.. (2010). Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with total therapy (TT) protocols.. Journal of Clinical Oncology. 28(15_suppl). 8116–8116. 1 indexed citations

13.

Anaissie, Elias, Frits van Rhee, Antje Hoering, et al.. (2010). Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B. Blood. 116(21). 368–368. 6 indexed citations

14.

Rhee, Frits van, Jackie Szymonifka, Elias Anaissie, et al.. (2010). Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 116(8). 1220–1227. 83 indexed citations

15.

Nair, Bijay, John D. Shaughnessy, Yiming Zhou, et al.. (2009). Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood. 113(26). 6572–6575. 15 indexed citations

16.

Pineda‐Roman, Mauricio, Maurizio Zangari, Frits van Rhee, et al.. (2008). VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 22(7). 1419–1427. 99 indexed citations

17.

Barlogie, Bart, Elias Anaissie, Frits van Rhee, et al.. (2007). Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology. 138(2). 176–185. 245 indexed citations

18.

Ghosh, Samiran, Dennis W. Hill, Nathan Petty, et al.. (2006). Statistical approach to metabonomic analysis of rat urine following surgical trauma. Journal of Chemometrics. 20(3-4). 87–98. 7 indexed citations

19.

Mitchell, Lex A., David F. Grant, Russell B. Melchert, Nathan Petty, & Richard H. Kennedy. (2002). Linoleic acid metabolites act to increase contractility in isolated rat heart. Cardiovascular Toxicology. 2(3). 219–229. 19 indexed citations

20.

Mitchell, Lex A., David F. Grant, Russell B. Melchert, Nathan Petty, & Richard H. Kennedy. (2002). Linoleic Acid Metabolites Act to Increase Contractility in Isolated Rat Heart. Cardiovascular Toxicology. 2(3). 219–230. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact